|
This is an index of reports of adverse events (side effects, adverse reactions, etc.) related to Velcade (Bortezomib). Click on the relevant link below to view a selection of reports according to the event's seriousness level and/or the nature of the side effect / adverse reaction. Or scroll down to view a sample of recent reports further on this page.
Our database includes reports from Jan 2007 to Dec 2007. The information is not vetted and should not be cosidered as verified clinical evidence.
All cases (1063)
Cases resulting in a serious event (1060)
Cases resulting in death (341)
Cases resulting in life threatening events (147)
Cases resulting in hospitalization (588)
Cases resulting in disability (32)
Cases resulting in other serious reactions (363)
Below is a sample of reports where side effects / adverse reactions may be related to Velcade (Bortezomib). For a complete list and/or a specific selection of reports, please use the links in the index above.
Adverse event in 84 year old female receiving Velcade (Bortezomib)
Reported by a physician from Italy on 2007-10-31
Patient: 84 year old female
Adverse reactions / side effects: Psychomotor Hyperactivity, Coma, Depressed Level of Consciousness, Sensory Loss, Cognitive Disorder
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Fentanyl
Indication: Drug USE FOR Unknown Indication
Melphalan(melphalan) Vial
Indication: Multiple Myeloma
Prednisone TAB
Indication: Multiple Myeloma
Velcade
Indication: Multiple Myeloma
Other drugs received by patient: Lansoprazole; Vasoretic (Hydrochloride, Enalapril Maleate); Aspirin; Plasil (Metoclopramide Hydrochloride)
Adverse event in 53 year old male receiving Velcade (Bortezomib)
Reported by a physician from Germany on 2007-10-31
Patient: 53 year old male, weighing 100.0 kg (220.0 pounds)
Adverse reactions / side effects: Disseminated Intravascular Coagulation, Hepatic Failure, Continuous Haemodiafiltration, Pulmonary Embolism, Pupils Unequal, Left Ventricular Failure, Erythema, Multi-Organ Failure, Acute Respiratory Distress Syndrome, Thrombocytopenia, Sinusitis, Acute Respiratory Failure, Renal Failure Acute, Tachyarrhythmia, Hypotension, Skin Disorder, Mastoiditis, Haemodialysis, Cardiac Failure, Staphylococcal Infection, Septic Shock, Purulent Discharge
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Cyclophosphamide
Dosage: 1800.00 mg, intravenous
Indication: Plasmacytoma
Start date: 2007-07-02
End date: 2007-07-02
Dexamethasone
Dosage: 40.00 mg, oral
Administration route: Oral
Indication: Plasmacytoma
Start date: 2007-06-02
Velcade
Dosage: 2.60 mg, intravenous
Indication: Plasmacytoma
Start date: 2007-07-02
End date: 2007-07-02
Other drugs received by patient: Dipyrone TAB; Buprenorphine Hydrochloride; Pantoprazole Sodium
Adverse event in 67 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-31
Patient: 67 year old male, weighing 62.0 kg (136.4 pounds)
Adverse reactions / side effects: Pneumonia, Gastrointestinal Haemorrhage, Blood Lactate Dehydrogenase Increased, Alanine Aminotransferase Increased, Condition Aggravated, Multiple Myeloma, Disease Progression, Tumour Lysis Syndrome, Aspartate Aminotransferase Increased, Blood Uric Acid Increased, Pneumonia Necrotising, Haemorrhagic Diathesis, Platelet Count Decreased
Adverse event resulted in: death
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Dexamethasone; Betamethasone; Orgaran
Adverse event in 66 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-31
Patient: 66 year old male, weighing 67.0 kg (147.4 pounds)
Adverse reactions / side effects: White Blood Cell Count Decreased, Pneumonia, Blood Lactate Dehydrogenase Increased, Alanine Aminotransferase Increased, Anaemia, Protein Total Decreased, Hypoaesthesia, Purpura, Constipation, Oral Herpes, Platelet Count Decreased, Oedema, Enterocolitis, Neutrophil Count Decreased, Lymphocyte Count Decreased
Suspect drug(s):
Decadron
Dosage: 20.00 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-03-06
End date: 2007-04-07
Velcade
Dosage: 2.00 mg, intravenous, 1.30 mg/m2, intravenous
Indication: Multiple Myeloma
Start date: 2007-03-06
End date: 2007-04-06
Velcade
Dosage: 2.00 mg, intravenous, 1.30 mg/m2, intravenous
Indication: Multiple Myeloma
Start date: 2007-07-20
End date: 2007-07-20
Other drugs received by patient: Levofloxacin; Baktar (Sulfamethoxazole, Trimethoprim); Laxoberon (Sodium Picosulfate); Sennoside A (Sennoside A); Pantosin (Pantethine); Platelets; RED Blood Cells; Lasix; Aldactone
Adverse event in 75 year old female receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-31
Patient: 75 year old female, weighing 47.0 kg (103.4 pounds)
Adverse reactions / side effects: Face Oedema, Malaise, Pharyngeal Oedema, Visual Disturbance, Bone Pain, Oedema, Hyponatraemia, Blindness Unilateral
Adverse event resulted in: hospitalization
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Dexamethasone; Diflucan; Baktar (Sulfamethoxazole, Trimethoprim); Allopurinol; Alfarol (Alfacalcidol); Omeprazole; Promac (Polaprezinc); Kamag G (Magnesium Oxide)
Adverse event in female receiving Velcade (Bortezomib)
Reported by a health professional (non-physician/pharmacist) from United States on 2007-10-31
Patient: female, weighing 74.4 kg (163.7 pounds)
Adverse reactions / side effects: Syncope, Vomiting, Nausea, Dehydration, Nervous System Disorder, Convulsion
Adverse event resulted in: hospitalization
Suspect drug(s):
Taxotere
Dosage: 137 mg q3weeks iv
Indication: Neoplasm Malignant
Start date: 2007-10-24
Velcade
Dosage: 2.9mg d1 d8 q21 d iv
Start date: 2007-10-24
Adverse event in 61 year old receiving Velcade (Bortezomib)
Reported by a physician from Netherlands on 2007-10-31
Patient: 61 year old
Adverse reactions / side effects: Mucosal Inflammation, Dyspnoea, Respiratory Failure, Hypotension, Febrile Neutropenia
Adverse event resulted in: life threatening event
Suspect drug(s):
Melphalan (Melphalan) Vial
Dosage: 100.00 mg/m2
Indication: Multiple Myeloma
Start date: 2007-09-10
End date: 2007-09-11
Velcade
Indication: Multiple Myeloma
Other drugs received by patient: Valacyclovir; Lorazepam; Zolpidem (Zolpiden)
Adverse event in female receiving Velcade (Bortezomib)
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2007-10-31
Patient: female
Adverse reactions / side effects: Dizziness, Circulatory Collapse
Suspect drug(s):
Velcade (Bortezomib)
Adverse event in 62 year old female receiving Velcade (Bortezomib)
Reported by a health professional (non-physician/pharmacist) from United States on 2007-10-31
Patient: 62 year old female, weighing 48.7 kg (107.2 pounds)
Adverse reactions / side effects: Pneumonia, Condition Aggravated, Troponin Increased, Respiratory Distress, Disease Progression, Pulmonary Oedema, Pleural Effusion, non-Small Cell Lung Cancer, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Velcade (Bortezomib)
Adverse event in 47 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-31
Patient: 47 year old male, weighing 69.0 kg (151.8 pounds)
Adverse reactions / side effects: Hot Flush, Neuropathy Peripheral, C-Reactive Protein Increased, Platelet Count Decreased, Hiccups, Hypertension
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Dexamethasone; Serotone (Azasetron Hydrochloride); Famotidine; Methycobal (Mecobalamin); Shakuyakukanzoutou (Herbal Extracts Nos)
Adverse event in 60 year old female receiving Velcade (Bortezomib)
Reported by a physician from France on 2007-10-29
Patient: 60 year old female
Adverse reactions / side effects: Guillain-Barre Syndrome
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Thalidomide; Dexamethasone
Adverse event in 70 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-29
Patient: 70 year old male, weighing 52.3 kg (115.1 pounds)
Adverse reactions / side effects: Diarrhoea, Blood Lactate Dehydrogenase Increased, Blood Uric Acid Increased, Platelet Count Decreased, Pyrexia, Infection
Suspect drug(s):
Velcade
Dosage: 1.30 mg/m2, intravenous; 2.00 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-04-06
End date: 2007-04-06
Velcade
Dosage: 1.30 mg/m2, intravenous; 2.00 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-04-13
End date: 2007-05-21
Other drugs received by patient: Orgadrone (Dexamethasone Sodium Phosphate); Aspirin; Allopurinol; Kytril; Epogin (Epoetin Beta) Injection; Maxipime; Zometa; Hydrocortisone Sodium Succinate; Lasix (Furosemide) Injection; Baktar (Sulfamethoxazole, Trimethoprim) Tablet
Adverse event in 44 year old female receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-29
Patient: 44 year old female, weighing 70.0 kg (154.0 pounds)
Adverse reactions / side effects: White Blood Cell Count Decreased, Viral Infection, Diarrhoea, Nausea, Drug Hypersensitivity, Pain, Platelet Count Decreased, Hypoaesthesia, Parotitis, Herpes Zoster
Adverse event resulted in: hospitalization
Suspect drug(s):
Velcade
Dosage: 2.00 mg, intravenous; 1.70 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-06-04
End date: 2007-06-14
Velcade
Dosage: 2.00 mg, intravenous; 1.70 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-07-16
End date: 2007-07-26
Other drugs received by patient: Dexamethasone; Alfarol (Alfacalcidol); Famotidine
Adverse event in 50 year old male receiving Velcade (Bortezomib)
Reported by a physician from France on 2007-10-29
Patient: 50 year old male
Adverse reactions / side effects: Renal Tubular Disorder, Pyrexia
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Dexamethasone
Adverse event in male receiving Velcade (Bortezomib)
Reported by a physician from United States on 2007-10-29
Patient: male, weighing 77.4 kg (170.3 pounds)
Adverse reactions / side effects: Mucosal Inflammation, Viral Infection, Oesophagitis
Adverse event resulted in: hospitalization
Suspect drug(s):
Tipifarnib(tipifarnib) Oral Drug Unspecified Form
Dosage: 600.00 mg, oral
Administration route: Oral
Indication: Acute Myeloid Leukaemia
Start date: 2007-09-25
End date: 2007-10-07
Velcade
Dosage: 1.90 mg, intravenous
Indication: Acute Myeloid Leukaemia
Start date: 2007-09-25
End date: 2007-10-05
Adverse event in 50 year old male receiving Velcade (Bortezomib)
Reported by a physician from Portugal on 2007-10-29
Patient: 50 year old male
Adverse reactions / side effects: Hypotension, Pyrexia, Tremor
Suspect drug(s):
Velcade (Bortezomib)
Other drugs received by patient: Antihistamines; Corticosteroids
Adverse event in -1 year old receiving Velcade (Bortezomib)
Reported by a physician from Spain on 2007-10-29
Patient: -1 year old
Adverse reactions / side effects: Death
Adverse event resulted in: death
Suspect drug(s):
Velcade (Bortezomib)
Adverse event in female receiving Velcade (Bortezomib)
Reported by a physician from United States on 2007-10-29
Patient: female, weighing 78.0 kg (171.6 pounds)
Adverse reactions / side effects: Blood Potassium Decreased, Diarrhoea, Dyskinesia, Hypotension, Blood Bicarbonate Decreased
Adverse event resulted in: hospitalization
Suspect drug(s):
Velcade
Dosage: 2.00 mg, intravenous, 2.60 mg, intravenous, 2.50 mg, intravenous, 2.00 mg, intravenus
Indication: Multiple Myeloma
Start date: 2005-12-05
End date: 2006-10-10
Velcade
Dosage: 2.00 mg, intravenous, 2.60 mg, intravenous, 2.50 mg, intravenous, 2.00 mg, intravenus
Indication: Multiple Myeloma
Start date: 2006-10-13
End date: 2006-11-10
Velcade
Dosage: 2.00 mg, intravenous, 2.60 mg, intravenous, 2.50 mg, intravenous, 2.00 mg, intravenus
Indication: Multiple Myeloma
Start date: 2006-12-11
End date: 2007-01-11
Velcade
Dosage: 2.00 mg, intravenous, 2.60 mg, intravenous, 2.50 mg, intravenous, 2.00 mg, intravenus
Indication: Multiple Myeloma
Start date: 2007-01-15
End date: 2007-05-11
Other drugs received by patient: Thalidomide; Dexamethasone
Adverse event in 63 year old male receiving Velcade (Bortezomib)
Reported by a physician from Netherlands on 2007-10-29
Patient: 63 year old male, weighing 92.0 kg (202.4 pounds)
Adverse reactions / side effects: Hyperglycaemia, Viral Myocarditis, Hyponatraemia, Constipation
Adverse event resulted in: death
Suspect drug(s):
Dexamethasone
Dosage: 40.00 mg, oral
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2007-10-09
End date: 2007-10-20
Doxorubicin HCL
Dosage: 13.00 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-10-09
End date: 2007-10-12
Velcade
Dosage: 2.70 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-10-09
End date: 2007-10-19
Other drugs received by patient: Hydrochlorothiazide; Simvastatin; Metformin HCL; Glimepiride; Valacyclovir
Adverse event in 40 year old male receiving Velcade (Bortezomib)
Reported by a physician from France on 2007-10-29
Patient: 40 year old male, weighing 82.0 kg (180.4 pounds)
Adverse reactions / side effects: Cardio-Respiratory Arrest, Cardiac Amyloidosis
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Dexamethasone
Dosage: 40.00 mg,
Indication: Multiple Myeloma
Start date: 2006-07-14
End date: 2006-09-18
Velcade
Dosage: 1.30 mg/m2,
Indication: Multiple Myeloma
Start date: 2006-07-14
End date: 2006-09-25
Adverse event in 64 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-29
Patient: 64 year old male, weighing 71.0 kg (156.2 pounds)
Adverse reactions / side effects: Insomnia, Hiccups, Platelet Count Decreased, Constipation, Herpes Zoster, Loss of Consciousness
Suspect drug(s):
Dexamethasone TAB
Dosage: 20.00 mg, oral
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2007-06-11
End date: 2007-07-06
Velcade
Dosage: 2.20 mg, intravenous
Indication: Multiple Myeloma
Start date: 2007-06-11
End date: 2007-07-05
Other drugs received by patient: Allopurinol; Famotidine; Baktar (Sulfamethoxazole, Trimethoprim); Zolpidem Tartrate; Primperan TAB; Mucosta (Rebamipide); Pantosin (Pantethine); Magnesium Oxide (Magnesium Oxide); Pursennid (Senna Leaf); Insulin Human (Insulin Human); Kinedak (Epalrestat); Aspirin; Lasix; Aldactone; Enalapril Maleate; Medet (Metformin Hydrochloride); Amlodipine Besylate
Adverse event in female receiving Velcade (Bortezomib)
Reported by a physician from Germany on 2007-10-26
Patient: female, weighing 55.0 kg (121.0 pounds)
Adverse reactions / side effects: Pneumonia, Upper Gastrointestinal Haemorrhage, Gastric Haemorrhage
Adverse event resulted in: death, life threatening event
Suspect drug(s):
Cyclophosphamide
Dosage: 40.00 mg, oral
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2007-08-17
End date: 2007-08-17
Dexamethasone
Dosage: 40.00 mg,
Indication: Multiple Myeloma
Start date: 2007-08-17
End date: 2007-08-29
Velcade
Indication: Multiple Myeloma
Start date: 2007-08-17
End date: 2007-08-24
Other drugs received by patient: Metronidazole; Fluconazole; Mesna; Granisetron HCL; Ciprofloxacin; Diclofenac (Diclofenac); Mirtazapine; Dipyrone TAB; Fentanyl; Pantoprazole Sodium; Enoxaparin Sodium; Metoclopramide (Metoclopramide)
Adverse event in female receiving Velcade (Bortezomib)
Reported by a physician from Germany on 2007-10-26
Patient: female
Adverse reactions / side effects: Pulmonary Alveolar Haemorrhage
Suspect drug(s):
Velcade (Bortezomib)
Adverse event in 75 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-26
Patient: 75 year old male, weighing 58.0 kg (127.6 pounds)
Adverse reactions / side effects: Neurogenic Bladder, Interstitial Lung Disease, Blood Beta-D-Glucan Increased
Adverse event resulted in: disablity
Suspect drug(s):
Velcade (Bortezomib)
Adverse event in 71 year old male receiving Velcade (Bortezomib)
Reported by a physician from Japan on 2007-10-26
Patient: 71 year old male
Adverse reactions / side effects: Tumour Lysis Syndrome, Bone Marrow Failure
Suspect drug(s):
Decadron
Indication: Multiple Myeloma
Velcade
Indication: Multiple Myeloma
Other drugs received by patient: Decadron
|
